A Review of Immunotherapy for Stage III and Metastatic Non‐Small Cell Lung Cancer and the Rationale for the ECOG‐ACRIN EA5181 Study

ECOG‐ACRIN EA5181 is a phase III prospective, randomized trial that randomizes patients undergoing chemo/radiation for locally advanced non‐small cell lung cancer (LA‐NSCLC) to concomitant durvalumab or no additional therapy, with both arms receiving 1 year of consolidative durvalumab. Radiation dos...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Varlotto, John M., Sun, Zhuoxin, Ky, Bonnie, Upshaw, Jenica, Katz, Sharyn I., Fitzgerald, Thomas J., Wakelee, Heather, Diehn, Maximilian, Mankoff, David A., Lovely, Christine, Belani, Chandra, Oettel, Kurt, Masters, Gregory, Ramalingam, Suresh, Pennell, Nathan A.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Lung Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176975/
https://ncbi.nlm.nih.gov/pubmed/33594771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13725
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados